08:57 AM EDT, 05/22/2026 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) , down 6% in U.S. pre-market trading, is showcasing three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29-June 2 in Chicago, the company said on Friday.

The presentations will include two poster presentations featuring data from BriaCell's ongoing Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, Bria-ABC, and one poster highlighting further analyses of Phase 2 data.

"Our positive clinical data across six presentations or abstracts at the ASCO 2026 Annual Meeting highlight the progress we are making in our clinical programs," said William Williams, BriaCell's chief executive. "These data reflect our commitment to advancing innovative therapeutic options for patients with cancer patients who need better treatments."

BriaCell shares were last seen down US$0.22, to US$3.50 in New York trading.